NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Yann d’Hervé takes over responsibility for the Health Care business at Evonik, effective July 1
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Ibara will drive AI-powered clinical research innovation
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
Glenmark released Picture Post Cards on World Vitiligo Day
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Subscribe To Our Newsletter & Stay Updated